A Novel Ruthenium-Fluvastatin Complex Downregulates SNCG Expression to Modulate Breast Carcinoma Cell Proliferation and Apoptosis via Activating the PI3K/Akt/mTOR/VEGF/MMP9 Pathway

Table 4

Hematological finding in female Swiss albino mice treated with the ruthenium-fluvastatin complex for a 28-day repeated-dose oral subacute toxicity study.

Parameters (±SEM)	Control	Ru-flu complex (200 mg)	Ru-flu complex (100 mg)	Ru-flu complex (50 mg)	Ru-flu complex (25 mg)
Hemoglobin (%)
Total RBC (×10^6/μ)		^#
Platelet count (×10^5/μ)
WBC (×10^3/μ)		^#
MCV (fL)
MCH (pg)
MCHC (%)
Neutrophil (%)
Eosinophil (%)
Monocytes (%)
Basophil (%)

. Results are analyzed by the -test and one-way ANOVA and confirmed by Dunnett’s multiple comparison test. MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; RBC: red blood cell; WBC: white blood cell. ^#Significant difference at , when compared with the control group.